Biomarkers hold the key to better clinical outcomes

With a number of therapeutics showing to be ineffective in up to 75% of the patients they are administered to, the necessity for personalized and precision medicine is obvious.

As the use of selection biomarkers can boost drug development success rates threefold, Cerba Research has expanded its portfolio to test beyond routine safety and efficacy parameters.

As a global partner for integrated clinical trial laboratory and diagnostic solutions, Cerba Research’s primary objective is to yield early scientific insights that advance the client’s protocol.

Cerba Research has developed an extensive portfolio of next-generation assays for targeted approaches or comprehensive immune profiling with multifactorial biomarkers. Take advantage of Cerba’s personalized service to acquire cutting-edge, dynamic and bespoke solutions grounded in expert science.

Optimize biomarker strategies for precision medicine

Besides monitoring the efficacy of a drug by PK & PD, biomarkers are becoming increasingly important and progressing rapidly to:

  • Aid in prognosis
  • Characterize mode of action
  • Guide dose selection
  • Monitor disease
  • Predict drug response
  • Stratify patients

Biomarkers hold the key to better clinical outcomes

Image Credit: Cerba Research

Streamline your development — and guarantee quality

Cerba Research’s quality-orientated approach includes analytically validated assays and GLP- and/or CLIA-certified labs. Tailoring the optimal solution, Cerba Research aims to meet client’s expectations in order to:

  • Assess method feasibility
  • Develop and validate customized assays
  • Obtain detailed sample analyses
  • Transfer assays developed in-house

Biomarkers hold the key to better clinical outcomes

Image Credit: Cerba Research

Cerba Research’s comprehensive solutions include:

  • Companion diagnostics
  • Customized and tailored assays
  • Quality assurance
  • Specialty testing
  • Scientific expertise

Biomarkers hold the key to better clinical outcomes

Image Credit: Cerba Research

Biomarkers hold the key to better clinical outcomes

Image Credit: Cerba Research

Gain insights to help tackle development challenges with Cerba Research’s integrated pharmacokinetic services

Absorption, distribution, metabolization and excretion (ADME) are essential to the safety and efficacy of any drug. Pharmacokinetic (PK) and pharmacodynamic (PD) assays are robust tools to better comprehend your drug’s mechanism of action (MOA) and efficacious dose regimen.

Cerba Research’s strategic alliance partnership with Frontage Lab, a true pioneer in the field, delivers the highest proficiency of experience in the development and implementation of PK, toxicity, bioanalytical and biomarker analyses.

Innovative platforms

  • ELISA platform
  • Ella ProteinSimple system
  • Immunohistochemistry platforms
  • LC-MS/MS
  • Luminex Magpix
  • MSD S600 Meso Scale Discovery
  • Quanterix Simoa HD1

Circulating biomarkers

Below are the majority of the circulating biomarkers Cerba Research currently tests for:

  • Human plasma
  • Human urine
  • Human serum
  • Human cell/tissue
  • Whole blood
  • Human CSF
  • BAL fluid

As new tests are frequently added, contact Cerba Research directly for a complete list.

As a partner, Cerba Research grants clients the power to offer new, life-changing therapies to patients across the globe. Cerba helps to transform the face of clinical development.

About Cerba Research

For over 35 years, Cerba Research has been setting the industry standard for exemplary clinical trial conduct. Today, across five continents, with a focus on precision medicine, we are changing the paradigm of the central lab’s role in complex clinical research.

From protocol inception through development and to market, our passionate experts deliver the highest quality specialized and personalized laboratory and diagnostic solutions. Partner with us for the most efficient strategy to actualize your biotech and pharmaceutical products sooner and improve the lives of patients worldwide.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Apr 13, 2022 at 12:01 PM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cerba Research. (2022, April 13). Biomarkers hold the key to better clinical outcomes. News-Medical. Retrieved on November 27, 2022 from https://www.news-medical.net/whitepaper/20220405/Biomarkers-hold-the-key-to-better-clinical-outcomes.aspx.

  • MLA

    Cerba Research. "Biomarkers hold the key to better clinical outcomes". News-Medical. 27 November 2022. <https://www.news-medical.net/whitepaper/20220405/Biomarkers-hold-the-key-to-better-clinical-outcomes.aspx>.

  • Chicago

    Cerba Research. "Biomarkers hold the key to better clinical outcomes". News-Medical. https://www.news-medical.net/whitepaper/20220405/Biomarkers-hold-the-key-to-better-clinical-outcomes.aspx. (accessed November 27, 2022).

  • Harvard

    Cerba Research. 2022. Biomarkers hold the key to better clinical outcomes. News-Medical, viewed 27 November 2022, https://www.news-medical.net/whitepaper/20220405/Biomarkers-hold-the-key-to-better-clinical-outcomes.aspx.

Other White Papers by this Supplier